Novo Nordisk’s ziltivekimab, an investigational human monoclonal antibody that targets the IL-6 ligand, a pro-inflammatory cytokine, to reduce cardiovascular inflammation, did not reduce the risk of major adverse cardiovascular events (MACE) in a Phase 3 trial. “Although ziltivekimab produced the expected biological effect, this did not result in MACE benefits in this population,” Martin Holst Lange, executive vice president, chief…